RNS Number : 1123N Roquefort Therapeutics PLC 18 January 2023

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer <u>and</u> to the FCA in Microsoft Word format if possible)^j

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ :			Roquefort Therapeutics PLC			
1b. Please indicate	if the issuer is a non-U	JK issuer (plea	se mark	with an "X" if appropria	te)	
Non-UK issuer						
2. Reason for the no	tification (please mark	the appropriate	box or b	ooxes with an "X")		
An acquisition or disposal of voting rights						Х
An acquisition or dis	posal of financial inst	ruments				
An event changing t	he breakdown of votir	ng rights				
Other (please specif	fy) ⁱⁱⁱ :					
3. Details of person	subject to the notifica	tion obligatior	ı ^{iv}			
Name			Abdelatif LACHAB			
City and country of registered office (if applicable)						
4. Full name of share	eholder(s) (if different fr	rom 3.) ^V				
Name						
City and country of registered office (if applicable)						
5. Date on which the threshold was crossed or reached ^{vi} :		17 January 2023				
6. Date on which issuer notified (DD/MM/YYYY):			18 January 2023			
7. Total positions of	person(s) subject to the	ne notification	obligati	ion		
	% of voting rights attached to shares (total of 8. A)	% of voting inthrough finating instrumer (total of 8.B 1 2)	ncial nts	Total of both in % (8.A + 8.B)	Total number of votin	ng
Resulting situation on the date on which threshold was crossed or reached	6			6	7,750,000	
Position of previous notification (if applicable)	5.6			5.6	7,200,000	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^{viii}					
A: Voting rights attached to shares					
Class/type of shares ISIN code (if possible)	Number of voting rights ^{ix}		% of voting rights		
	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	
	7,750,000		6%		
SURTOTAL 8 A	7 750	n nnn		6%	

OODIOIAL V. A	1,100,000	U /U

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))					
Type of financial instrument	Expiration date ^X	Exercise/ Conversion Period ^{xi}	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights	
		SUBTOTAL 8. B 1			
	•				

Type of financial instrument	Expiration date ^X	Exercise/ Conversion Period Xi	Physical or cash settlement ^{XII}	Number of voting rights	% of voting rights
	L		SUBTOTAL 8.B.2		

9. Information in relation applicable box with an "X")	n to the person subject to t	he notification obligation (please mark the	
Person subject to the notif	ication obligation is not contr	olled by any natural person o	or legal entity and does	V
not control any other under	rtaking(s) holding directly or i	ndirectly an interest in the (u	nderlying) issuer ^{xiii}	Х
	lertakings through which the vifectively held starting with the		person or legal entity	
(please add additional rows	s as necessary) ^{XİV}			
Name ^{XV}	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equ is higher than th notifiable thresho	e
				•

10. In case of proxy voting, please identify:		
Name of the proxy holder		
The number and % of voting rights held		
The date until which the voting rights will be held		

11. Additional information ^{XVI}				

Place of completion	London
Date of completion	18 January 2023

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLUWOWROVUAARR